Skip to main content

Table 1 Characteristics of patients with bmCRPC on AA with or without ALP-Bouncing

From: Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer

Variable all no ALP-Bouncing ALP-Bouncing p
Patients [n], (%) 84 50 (60) 34 (40) -
Age, median [years] (IQR) 69.0 (62.3–76.0) 68.0 (61.0–75.5) 70.5 (66.5–76.0) 0.304
Lnn. Metastases [n] (%) 45 (53.6) 27 (54.0) 18 (52.9) 0.924
Visceral Metastases [n] (%) 17 (20.2) 14 (28.0) 3 (8.8) 0.032
Pre CTX [n] (%) 39 (46.4) 24 (48.0) 15 (44.1) 0.726
Post CTX [n] (%) 45 (53.6) 26 (52.0) 19 (55.9) 0.726
Patients died [n] (%) 53 (63.1) 39 (78.0) 14 (41.2) -
Antiresorptive therapy [n] (%) 56 (66.7) 32 (64.0) 24 (70.6) 0.530
Zoledronic acid [n] (%) 42 (50.0) 24 (48.0) 18 (52.9) 0.821
Denosumab [n] (%) 14 (16.7) 8 (16.0) 6 (17.6)
Best clinical outcome [n] (%)     
CR 1 (1.2) 0 (0) 1 (2.9) <0.001
PR 51 (60.7) 22 (44.0) 29 (85.3)
SD 20 (23.8) 16 (32.0) 4 (11.8)
PD 12 (14.3) 12 (24.0) 0 (0)
ECOG (all) [n] (%)     
0 12 (14.3) 7 (14.0) 5 (14.7) 0.351
1 53 (63.1) 29 (58.0) 24 (70.6)  
2 29 (22.6) 14 (28.0) 5 (14.7)  
GS ≥ 8 [n] (%)a 45 (60.8) 29 (67.4) 16 (51.6) 0.169
PSA red. ≥ 50 % [n] (%) 47 (56.0) 19 (38.0) 28 (82.4) <0.001
PSA red. ≥ 90 % [n] (%) 22 (26.2) 6 (12.0) 16 (47.1) <0.001
Median PSA Baseline [ng/ml] (IQR) 174 (55–500) 105 (47–457) 151 (54–477) 0.824
Median LDH Baseline [U/l] (IQR) 287 (223–422) 290 (228–565) 252 (218–327) 0.125
Median ALP Baseline [U/l] (IQR) 155 (102–355) 171 (96–381) 154 (114–273) 0.895
ALP rising at 12 w AA [n] (%) 27 (33.3) 27 (57.4) 0 (0) -
LDH BL > UNL [n] (%) 58 (71.6) 37 (77.1) 21 (63.6) 0.187
LDH normalization [n] (%) 23 (39.0) 10 (27.0) 13 (59.1) 0.015
  1. aPatients for whom the GS-information was not available were excluded from GS analysis (n = 10)